Drug found 'remarkably' effective in common canine oral cancer
Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...
Medscape22d
Recurrent Squamous Cell Carcinoma In Situ of the Finger
A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...
Raleigh TV meteorologist paused on-air work for cancer treatment. Update on when he returns
The longtime local news meteorologist has been temporarily absent from broadcasts as he manages his health, but he’ll be back ...
EurekAlert!14d
New discovery reveals key protein that helps squamous cell carcinoma resist ferroptosis
A research team led by Prof. JIANG Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, ...
Managed Healthcare Executive13d
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
Managed Healthcare Executive8d
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
Targeted Oncology4d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
The American Journal of Managed Care14d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.